A Phase 2 interventional study of placebo and BI1356 low dose in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 25 sites in 9 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-15.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 25th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 86th largest by enrollment of the 96 interventional ones that give a count, is one of 11 that started in 2011, is one of 18 in phase 2, and was the 53rd registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to identify the dose of linagliptin in paediatric patients.
Other efficacy objectives include the comparison of the lowering effect of linagliptin low dose, high dose and placebo on the fasting plasma glucose (FPG) observed after 12 wk of treatment.
Furthermore, the study will investigate the pharmacokinetics (PK), the pharmacodynamics (PD) and the PK/PD relationship of linagliptin in the paediatric population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
linagliptin low dose for children once daily
Drug: BI1356 low dose
linagliptin high dose for children once daily
Drug: BI1356 high dose
matching placebo for each linagliptin dose once daily
Drug: placebo
comparison of different dosages of drug (low vs high) vs placebo
comparison of different dosages of drug (low vs high) vs placebo
comparison of different dosages of drug (low vs high) vs placebo
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment
Change from baseline in Glycosylated haemoglobin (HbA1c) \[%\] after 12 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
Time frame: Baseline and 12 weeks
Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State
DPP-4 inhibition (%) at trough at steady state is the relative change between the measurement of DPP-4 activity taken 0.5 hours before dosing at baseline and the first available on-treatment measurement of DPP-4 activity taken 0.5 hour before dosing at week 4, 8 or 12: DPP-4 inhibition (%) = 100 - (DPP-4 activity at week X / DPP-4 activity at baseline) x 100.
Time frame: Baseline and 4 weeks or 8 weeks or 12 weeks
Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment
Change from baseline in FPG (mmol/L) after 12 weeks of treatment with double-blind trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
Time frame: Baseline and 12 weeks
Randomised, double-blind, placebo-controlled parallel group dose-finding study of linagliptin over 12 weeks in children and adolescents, from 10 to 17 years of age, with type 2 diabetes mellitus. Due to serious Good clinical practice (GCP) breach, 1 patient excluded from all analyses. So protocol section has 40 subjects and participant flow has 39
| Milestone | Placebo | Linagliptin 1 mg | Linagliptin 5 mg |
|---|---|---|---|
| Started | 15 | 10 | 14 |
| Completed | 13 | 10 | 13 |
| Not completed | 2 | 0 | 1 |
| Withdrew: Other reasons | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Change from baseline in Glycosylated haemoglobin (HbA1c) \[%\] after 12 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
| Percentage of HbA1c | Placebo | Linagliptin 1 mg | Linagliptin 5 mg |
|---|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment | 0.45 ± 0.31 | -0.03 ± 0.38 | -0.19 ± 0.30 |
DPP-4 inhibition (%) at trough at steady state is the relative change between the measurement of DPP-4 activity taken 0.5 hours before dosing at baseline and the first available on-treatment measurement of DPP-4 activity taken 0.5 hour before dosing at week 4, 8 or 12: DPP-4 inhibition (%) = 100 - (DPP-4 activity at week X / DPP-4 activity at baseline) x 100.
| Percentage of DPP-4 inhibition | Placebo | Linagliptin 1 mg | Linagliptin 5 mg |
|---|---|---|---|
| Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State | — | 38.4 (26.9 to 48.8) | 78.9 (67.7 to 84.0) |
Change from baseline in FPG (mmol/L) after 12 weeks of treatment with double-blind trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
| mmol/L | Placebo | Linagliptin 1 mg | Linagliptin 5 mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment | 1.70 ± 0.85 | 1.39 ± 1.07 | -0.19 ± 0.83 |
Collected over From the first intake of study drug until 7 days after the last drug administration, up to 13 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/15 (6.7%) | 7/15 (46.7%) |
| Linagliptin 1 mg | — | 0/10 (0%) | 8/10 (80%) |
| Linagliptin 5 mg | — | 0/14 (0%) | 6/14 (42.9%) |
| Event | Placebo | Linagliptin 1 mg | Linagliptin 5 mg |
|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 1/15 | 0/10 | 0/14 |
| Event | Placebo | Linagliptin 1 mg | Linagliptin 5 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/15 | 3/10 | 0/14 |
| HeadacheNervous system disorders | 1/15 | 0/10 | 4/14 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/15 | 2/10 | 0/14 |
| Eye haemorrhageEye disorders | 0/15 | 1/10 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 1/10 | 0/14 |
| Conjunctivitis bacterialInfections and infestations | 0/15 | 1/10 | 0/14 |
| Blood creatinine increasedInvestigations | 0/15 | 1/10 | 0/14 |
| DizzinessNervous system disorders | 0/15 | 1/10 | 0/14 |
| ParaesthesiaNervous system disorders | 0/15 | 1/10 | 1/14 |
| MenorrhagiaReproductive system and breast disorders | 0/15 | 1/10 | 0/14 |
Treated set (TS) including all patients who were treated with at least one dose of study drug.
| Age, Continuous(Years) | Placebo | Linagliptin 1 mg | Linagliptin 5 mg | Total |
|---|---|---|---|---|
| Mean | 13.7 ± 2.0 | 14.0 ± 1.8 | 14.3 ± 2.1 | 14.0 ± 1.9 |
| Sex: Female, Male(Participants) | Placebo | Linagliptin 1 mg | Linagliptin 5 mg | Total |
|---|---|---|---|---|
| Female | 8 | 4 | 9 | 21 |
| Male | 7 | 6 | 5 | 18 |
The record gives a start of Apr 2011, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin